Fudan Zhangjiang: The price reduction of Liposomal Injection of Daurismo Hydrochloride shall not be less than 35%.

Fudan Zhangjiang announcement: The company has decided to gradually reduce the market retail price of the liposomal injection of duloxetine hydrochloride starting from May 1, 2025, and the price reduction will not be less than 35% compared to the previous bid price. In 2024, the sales revenue of this drug was approximately 210 million yuan, accounting for 29% of the company's total annual sales revenue. It is expected that the sales revenue of this drug in 2025 will decrease by more than 50% compared to the previous year, which may result in a risk of single-product loss for this drug in 2025.